Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

Guardado en:
Detalles Bibliográficos
Autores principales: M Rizzo, I Colomer-Asenjo, G Cabello-Molina, S Marín-López, M Sutil-Vega, C Roca-Guerrero, F Taibi-Hajjami, D García-Vega, M Panelo-Rubio, M Bonastre-Thio, A Martínez-Rubio
Formato: article
Lenguaje:EN
Publicado: Radcliffe Medical Media 2020
Materias:
Diseases of the circulatory (Cardiovascular) system
RC666-701
Acceso en línea:https://doaj.org/article/13a7748dffbb483bbadb61a818cf6ee8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:13a7748dffbb483bbadb61a818cf6ee8
record_format dspace
spelling oai:doaj.org-article:13a7748dffbb483bbadb61a818cf6ee82021-12-04T16:02:54ZTolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction10.15420/ecr.2020.15.1.PO91758-37641758-3756https://doaj.org/article/13a7748dffbb483bbadb61a818cf6ee82020-05-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2020.15.1.PO9https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764M RizzoI Colomer-AsenjoG Cabello-MolinaS Marín-LópezM Sutil-VegaC Roca-GuerreroF Taibi-HajjamiD García-VegaM Panelo-RubioM Bonastre-ThioA Martínez-RubioRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 15, Iss , Pp e32- (2020)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the circulatory (Cardiovascular) system
RC666-701
spellingShingle Diseases of the circulatory (Cardiovascular) system
RC666-701
M Rizzo
I Colomer-Asenjo
G Cabello-Molina
S Marín-López
M Sutil-Vega
C Roca-Guerrero
F Taibi-Hajjami
D García-Vega
M Panelo-Rubio
M Bonastre-Thio
A Martínez-Rubio
Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
format article
author M Rizzo
I Colomer-Asenjo
G Cabello-Molina
S Marín-López
M Sutil-Vega
C Roca-Guerrero
F Taibi-Hajjami
D García-Vega
M Panelo-Rubio
M Bonastre-Thio
A Martínez-Rubio
author_facet M Rizzo
I Colomer-Asenjo
G Cabello-Molina
S Marín-López
M Sutil-Vega
C Roca-Guerrero
F Taibi-Hajjami
D García-Vega
M Panelo-Rubio
M Bonastre-Thio
A Martínez-Rubio
author_sort M Rizzo
title Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
title_short Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
title_full Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
title_fullStr Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
title_full_unstemmed Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
title_sort tolerability profile and discontinuation causes of sacubitril/valsartan treatment in ‘real-life’ patients with heart failure and reduced ejection fraction
publisher Radcliffe Medical Media
publishDate 2020
url https://doaj.org/article/13a7748dffbb483bbadb61a818cf6ee8
work_keys_str_mv AT mrizzo tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT icolomerasenjo tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT gcabellomolina tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT smarinlopez tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT msutilvega tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT crocaguerrero tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT ftaibihajjami tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT dgarciavega tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT mpanelorubio tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT mbonastrethio tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
AT amartinezrubio tolerabilityprofileanddiscontinuationcausesofsacubitrilvalsartantreatmentinreallifepatientswithheartfailureandreducedejectionfraction
_version_ 1718372719859335168

Ejemplares similares